

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-17 (cancelled).

18 (currently amended). An antibody produced by administering an antigen comprising a mannan-binding lectin associated serine protease-2 (MASP-2 polypeptide) to an antibody producing animal.

19 (currently amended). An antibody that specifically ~~selectively~~ binds to MASP-2.

20 (original). The antibody of claim 18 or claim 19, wherein said antibody is a monoclonal antibody.

21 (original). The antibody of claim 18 or claim 19, said antibody being coupled to a compound comprising a detectable marker.

22 (previously presented). A pharmaceutical composition comprising the antibody of claims 18 or 19.

23 (currently amended). A method for detecting mannan-binding lectin associated serine protease-2 (MASP-2), said method

(a) obtaining a biological sample;

(b) contacting said biological sample with a MASP-2 polypeptide specific binding partner that specifically binds MASP-2, thereby forming complexes of said binding partner with said MASP-2 polypeptide, if any; and

(c) detecting said complexes of MASP-2 and said specific MASP-2 binding partner, if any, as an indication of the presence of mannan-binding lectin associated serine protease-2 in said sample,

where said binding partner is an antibody according to claim 19.

24-25 (cancelled).

26 (previously presented). The method of claim 23 for quantitative assay of MASP-2 or MASP-2 activity in biological

samples.

27-36 (cancelled).

37 (currently amended). A method for diagnosing a disorder associated with aberrant expression of MASP-2, comprising obtaining a biological sample from a patient, ~~and~~ measuring MASP-2 expression in said biological sample, wherein increased or decreased MASP-2 expression in said biological sample compared to a control indicates that said patient suffers from a disorder associated with aberrant expression of MASP-2;

correlating MASP-2 expression with presence or absence of said disorder and thereby diagnosing said disorder, where MASP-2 expression is measured by means of an assay reagent comprising an antibody according to claim 18 or claim 19.

38-39 (cancelled).

40 (currently amended). The antibody of claim 18 in which said antigen administered to said antibody-producing animal includes a determinant containing fragment of ~~peptide comprising a sequence of at least 16 amino acids in length from SEQ ID NO:2.~~

41 (previously presented). The antibody of claim 18 or claim 19 in which the antibody selectively inhibits the serine protease activity of MASP-2.

42 (currently amended). The antibody of claim 18 or claim 19 in which the antibody specifically ~~selectively~~ binds to the serine protease domain of SEQ ID NO:2.

43 (previously presented). The antibody of claim 18 or claim 19 in which the antibody inhibits MASP-2 catalyzed cleavage of complement factor C2 or C4.